Novel Amyloid Drug Improves Mid-Term Outcomes in ATTR Cardiomyopathy
Pivotal trial 'suggests the tantalizing possibility of genuine clinical improvement'
Stay updated with breaking news from Thibaud Damy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pivotal trial 'suggests the tantalizing possibility of genuine clinical improvement'
Lead author of the ATTRibute-CM trial says it was "robustly positive," and shows "the tantalizing possibility of genuine clinical improvements" for this progressive and fatal condition.
Business Scoop provides news and views on Business and Markets from New Zealand
Results also presented during late-breaking session at ESC Heart Failure congress 2023 ZURICH, SWITZERLAND, May 22, 2023 - (ACN Newswire) - Neurimmune announced today that primary results of its Phase 1 proof-of-concept study of NI006, a recombinant ...
Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy ...